Futura Medical PLC (OTCPK:FAMDF)

$ 0.381 -0.034 (-8.19%) Market Cap: 120.65 Mil Enterprise Value: 115.75 Mil PE Ratio: 0 PB Ratio: 10.38 GF Score: 41/100

Half Year 2024 Futura Medical PLC Earnings Presentation Transcript
Sep 10, 2024
Full Year 2023 Futura Medical PLC Earnings Call Transcript
Apr 10, 2024

$0.46 (-8.00%)

Earnings
Half Year 2023 Futura Medical PLC Earnings Call Transcript
Sep 19, 2023

$0.62 (-4.47%)

Earnings
Futura Medical PLC Special Call Transcript
Jun 26, 2023
Full Year 2022 Futura Medical PLC Earnings Call Transcript
Apr 05, 2023

$0.54 (-10.00%)

Earnings
Half Year 2022 Futura Medical PLC Earnings Call Transcript
Sep 13, 2022

$0.535 (-15.08%)

Earnings
Futura Medical PLC Highly Positive FM71 Phase 3 Study Results Presentation (Pre-Recorded) Transcript
Aug 31, 2022
Full Year 2021 Futura Medical PLC Earnings Call Transcript
Apr 26, 2022

$0.39

Earnings
Half Year 2021 Futura Medical PLC Earnings Call Transcript
Sep 29, 2021

$1

Earnings
Full Year 2020 Futura Medical PLC Earnings Call Transcript
Apr 14, 2021

$0.7

Earnings
Half Year 2020 Futura Medical PLC Earnings Call Transcript
Sep 16, 2020

$0.22

Earnings
Full Year 2019 Futura Medical PLC Earnings Call Transcript
Apr 01, 2020

$0.13

Earnings
Futura Medical plc - Special Call Transcript
Dec 10, 2019
Half Year 2019 Futura Medical PLC Earnings Call Transcript
Sep 11, 2019

$0.53 (+1.92%)

Earnings
Full Year 2018 Futura Medical PLC Earnings Call Transcript
Apr 10, 2019

$0.25

Earnings

Half Year 2022 Futura Medical PLC Earnings Call Transcript

Sep 13, 2022 / 09:00AM GMT

Release Date Price: $0.535 (-15.08%)

Transcript

James Henry Barder

Futura Medical plc - CEO & Executive Director

Okay. Well, good morning, everybody, and welcome to the Futura webcast for our interim results for 6 months ending 30th of June 2022.

I'm delighted to be joined by Angela Hildreth, our FD and COO; and also by Ken James, our Executive Director and Head of R&D.

So without further ado, let's move on to Slide 4. A little bit of Futura and corporate overview. We describe ourselves as a virtual organization. We have 13 staff and low overheads. We tend to subcontract a (inaudible), including our contract manufacturer, and we currently have around 30 consultants that we call on over when we need them. Our key sort of expertise is applying skin science to deliver novel topical clinically proven treatments and DermaSys is kind of our brand that embodies that. We've got an experienced team, and we're very much focused on developing clinically proven innovations, which we then look to license that to commercial partners.

Our main product, MED3000, is a topical gel for erectile dysfunction, and it now has U.K. and EU

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.